OBJECTIVE To evaluate the clinical efficacy of modified Zhujing Pills in the treatment of dry age-related macular degeneration (AMD) of liver and kidney insufficiency type.
METHODS 64 patients with dry AMD of liver and kidney insufficiency type were randomly divided into an experimental group and a control group, 32 patients each. The control group was given oral treatment with Laishiding capsules, and the experimental group was given oral treatment with modified Zhujing Pills granules. The treatment course for both groups was 3 months. Before and after treatment, the patients in the two groups were observed for TCM syndrome scores, visual acuity, fundus autofluorescence (AF), changes in drusen area within 5 mm of the fovea, and plasma superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity and malondialdehyde (MDA) levels.
RESULTS After treatment, the scores of TCM syndromes in the experimental group were significantly reduced (P < 0.05, P < 0.01), and the efficacy of TCM syndromes was better than that of the control group (P < 0.01); the visual acuity of the patients in the experimental group was significantly improved, AF was significantly weakened and the area of drusen was reduced (P < 0.05, P < 0.01), which were better than those in the control group (P < 0.05); the plasma SOD and GSH-Px activities of the experimental group were increased, and the MDA level was significantly lowered (P < 0.05, P < 0.01), which were better than the control group (P < 0.05).
CONCLUSION Modified Zhujing Pills can reduce fundus AF intensity, decrease macular drusen area, improve visual acuity, and reduce TCM syndrome scores in patients with dry AMD. The therapeutic mechanism may be related to its antioxidant effect.
DownLoad: